Its differential regulation of pre-mRNA splicing in MM and KMM cells suggests that FAM50A may act as a context-dependent modulator of oncogenic pathways, particularly in the context of KSHV-driven transformation. This evidence concerns the gene FAM50A and Miyoshi myopathy.